AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7714086 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH‐a)
Number of subjects: 33
Study 7714086 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills (OCPs)
Number of subjects: 33
Study 7714086 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of OCPs and GnRH‐a
Number of subjects: 33
Study 7714086 — intervention group
Group type: COMPARATOR
Intervention: OCPs alone
Number of subjects: 33
Study 2692963 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms ethinyl estradiol (EE) and 1.0 mg norethindrone (NE)
Number of subjects: 192
Study 2692963 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 micrograms ethinyl estradiol (EE) and 1.0 mg norethindrone (NE)
Number of subjects: 192
Study 2692963 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 micrograms ethinyl estradiol (EE) and 0.5 mg norethindrone (NE)
Number of subjects: 192
Study 589167 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine, 160 mg/day maximum plateau dose
Number of subjects: 50
Study 589167 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine, <100 ng/ml concentration
Number of subjects: 50
Study 589167 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 50
Study 31291507 — intervention group
Group type: EXPERIMENTAL
Intervention: SystemCHANGE™ intervention
Number of subjects: 89
Study 31291507 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 89
Study 30587959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized glycopyrrolate (GLY) 25 μg BID
Number of subjects: 1294
Study 30587959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized glycopyrrolate (GLY) 50 μg BID
Number of subjects: 1294
Study 30587959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1294
Study 29410921 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP with SensAwake technology
Number of subjects: 65
Study 29410921 — intervention group
Group type: COMPARATOR
Intervention: CPAP without SensAwake technology
Number of subjects: 65
Study 25779750 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg twice a day
Number of subjects: 237
Study 25779750 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice a day
Number of subjects: 237
Study 25779750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 25779750 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI substudy (both apremilast doses)
Number of subjects: 237
Study 25779750 — intervention group
Group type: EXPERIMENTAL
Intervention: Both apremilast doses
Number of subjects: 237
Study 25779750 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment groups
Number of subjects: 237
Study 23052714 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (MMC)
Number of subjects: 64
Study 23052714 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAC)
Number of subjects: 64
Study 22077680 — intervention group
Group type: EXPERIMENTAL
Intervention: LED activation for 40 or 20 seconds (1,200 mW/cm2)
Number of subjects: 30
Study 22077680 — intervention group
Group type: EXPERIMENTAL
Intervention: Halogen lamp (QTH) activation for 40 seconds (700 mW/cm)
Number of subjects: 30
Study 22077680 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage for 24 hours
Number of subjects: 30
Study 22077680 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage for 6 months
Number of subjects: 30
Study 18847340 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral nimodipine
Number of subjects: 106
Study 18847340 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nimodipine
Number of subjects: 106
Study 18694222 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced internet videoconferencing software and improved network connectivity
Number of subjects: 0
Study 18694222 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel combinations of existing open source solutions
Number of subjects: 0
Study 18694222 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified installation, configuration, and operation of videoconferencing
Number of subjects: 0
Study 15541126 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 48
Study 15541126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 11358646 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E(2)) 1 mg/day and 2 mg/day
Number of subjects: 33
Study 11358646 — intervention group
Group type: COMPARATOR
Intervention: Estradiol (E(2)) 2 mg/day plus 300 mg/day natural progesterone (P)
Number of subjects: 33
Study 11358646 — intervention group
Group type: COMPARATOR
Intervention: Estradiol (E(2)) 2 mg/day plus 5 mg/day medroxyprogesterone acetate (MPA)
Number of subjects: 33
Study 9625339 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (10 mg/kg then 2.5 mg/kg once daily)
Number of subjects: 50
Study 9625339 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (4 mg/kg then 2 mg/kg twice daily)
Number of subjects: 50
Study 7908778 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 2 sprays/nostril q24h
Number of subjects: 294
Study 7908778 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 2 sprays/nostril q12h
Number of subjects: 294
Study 7908778 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chlorpheniramine maleate 12 mg q12h
Number of subjects: 294
Study 7908778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study 3261158 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic injection sclerotherapy (FIS)
Number of subjects: 70
Study 3261158 — intervention group
Group type: COMPARATOR
Intervention: Rigid scope technique (RIS)
Number of subjects: 70
Study 31219367 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (HAL; 3 mg)
Number of subjects: 30
Study 31219367 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine (FLU; 3 mg)
Number of subjects: 30
Study 31219367 — intervention group
Group type: COMPARATOR
Intervention: Amphetamine (AMPH; 20 mg)
Number of subjects: 30
Study 27967270 — intervention group
Group type: EXPERIMENTAL
Intervention: β-alanine supplementation
Number of subjects: 22
Study 27967270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 26456372 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 100 μg, 250 μg, or 500 μg once daily
Number of subjects: 3802
Study 26456372 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) 400 μg or 500 μg twice daily
Number of subjects: 3802
Study 26456372 — intervention group
Group type: COMPARATOR
Intervention: Montelukast 10 mg once daily
Number of subjects: 3802
Study 22421315 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulations with debriefing and Advanced Cardiac Life Support course
Number of subjects: 14
Study 22421315 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulations with debriefing
Number of subjects: 14
Study 22421315 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Cardiac Life Support course
Number of subjects: 14
Study 22421315 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional interventions)
Number of subjects: 14
Study 21505506 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-glucan-enriched foods
Number of subjects: 24
Study 21505506 — intervention group
Group type: COMPARATOR
Intervention: Rice bran-enriched foods
Number of subjects: 24
Study 19097918 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent-grafts
Number of subjects: 81
Study 19097918 — intervention group
Group type: COMPARATOR
Intervention: Bare stents
Number of subjects: 81
Study 16269428 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen 500 mg twice daily
Number of subjects: 511
Study 16269428 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 511
Study 14550680 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (maximum dose 600 mg/day)
Number of subjects: 165
Study 14550680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 14550680 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 165
Study 11108760 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement (CIM) therapy
Number of subjects: 20
Study 11108760 — intervention group
Group type: COMPARATOR
Intervention: Traditional upper-extremity (UE) therapies
Number of subjects: 20
Study 8725454 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy followed by surgery (ES + S)
Number of subjects: 33
Study 8725454 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (SA)
Number of subjects: 33
Study 1305840 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (with or without codeine)
Number of subjects: 125
Study 1305840 — intervention group
Group type: COMPARATOR
Intervention: NSAI (Piroxicam, Indometazine, Ketoprofen, Diclofenac)
Number of subjects: 125
Study 3987177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg every 6 hours)
Number of subjects: 9
Study 3987177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice a day)
Number of subjects: 9
Study 3987177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29846604 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% transdermal testosterone gel applied daily for 3 years
Number of subjects: 0
Study 29846604 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied daily for 3 years
Number of subjects: 0
Study 29846604 — intervention group
Group type: COMPARATOR
Intervention: Comparison between testosterone and placebo
Number of subjects: 0
Study 26406203 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling to the lumbar multifidus muscles using a deep insertion technique with 4 needles (2 on each side of the spine), needles left in situ for 10 minutes
Number of subjects: 28
Study 26406203 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 24131367 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrastaurin (50 ng/ml)
Number of subjects: 21
Study 24131367 — intervention group
Group type: COMPARATOR
Intervention: Neoral (Calcineurin inhibitor)
Number of subjects: 21
Study 24131367 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrastaurin
Number of subjects: 21
Study 23150707 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation with fluorouracil (FU) plus mitomycin (MMC)
Number of subjects: 649
Study 23150707 — intervention group
Group type: COMPARATOR
Intervention: Induction plus concurrent fluorouracil (FU) plus cisplatin (CDDP)
Number of subjects: 649
Study 20694446 — intervention group
Group type: EXPERIMENTAL
Intervention: Tier 1 Program of Project P.A.T.H.S. (experimental group)
Number of subjects: 3170
Study 20694446 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3170
Study 17664851 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein hydrolysate containing Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP)
Number of subjects: 24
Study 17664851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16143741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine exposure
Number of subjects: 717
Study 12898896 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) examination
Number of subjects: 15
Study 12898896 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT) examination
Number of subjects: 15
Study 12898896 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of US and CT
Number of subjects: 15
Study 10340153 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine patch
Number of subjects: 34
Study 10340153 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 34
Study 7588427 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin alone
Number of subjects: 10
Study 7588427 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin + hydrocortisone
Number of subjects: 10
Study 7588427 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone alone
Number of subjects: 10
Study 1827451 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatril 25 mg every 12 h (group 1)
Number of subjects: 16
Study 1827451 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatril 100 mg every 12 h (group 2)
Number of subjects: 16
Study 1827451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7015141 — intervention group
Group type: EXPERIMENTAL
Intervention: Halsted radical mastectomy
Number of subjects: 701
Study 7015141 — intervention group
Group type: COMPARATOR
Intervention: Quadrantectomy with axillary dissection and radiotherapy
Number of subjects: 701
Study 29485289 — intervention group
Group type: EXPERIMENTAL
Intervention: Community treatment orders
Number of subjects: 5548
Study 29124549 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection of the primary tumor
Number of subjects: 65543
Study 29124549 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-agent chemotherapy with surgical resection
Number of subjects: 65543
Study 29124549 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy with surgical resection
Number of subjects: 65543
Study 29124549 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection of the primary tumor (multivariate analysis)
Number of subjects: 65543
Study 27811855 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking exercise training and weekly exercise counseling
Number of subjects: 111
Study 27811855 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 111
Study 24351375 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.2 μg/kg/hr (high dose)
Number of subjects: 24
Study 24351375 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.4 μg/kg/hr (low dose)
Number of subjects: 24
Study 24351375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24351375 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (combined high and low dose)
Number of subjects: 24
Study 24351375 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 24
Study 22811306 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills
Number of subjects: 42
Study 22811306 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive patches
Number of subjects: 42
Study 22811306 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal rings
Number of subjects: 42
Study 20553665 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol‐associated drink (lager based)
Number of subjects: 45
Study 20553665 — intervention group
Group type: COMPARATOR
Intervention: Fruit squash‐flavored drink (nonassociated)
Number of subjects: 45
Study 20553665 — intervention group
Group type: COMPARATOR
Intervention: Apple schnapps‐flavored drink (nonassociated)
Number of subjects: 45
Study 17667333 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 154
Study 17667333 — intervention group
Group type: EXPERIMENTAL
Intervention: K65R mutation
Number of subjects: 154
Study 17667333 — intervention group
Group type: EXPERIMENTAL
Intervention: L74V/I mutation
Number of subjects: 154
Study 16333174 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtenon anaesthesia
Number of subjects: 168
Study 16333174 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar anaesthesia
Number of subjects: 168
Study 12391059 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g/day for 4 days, then 2 g/day for 17 days)
Number of subjects: 10
Study 12391059 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 10
Study 12391059 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 10
Study 10608603 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity (HI, 80% of VO2max, n = 10)
Number of subjects: 26
Study 10608603 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity (LO, 40% of VO2max, n = 8)
Number of subjects: 26
Study 10608603 — intervention group
Group type: COMPARATOR
Intervention: Control (CON, n = 8)
Number of subjects: 26
Study 7860832 — intervention group
Group type: EXPERIMENTAL
Intervention: Vowel tokens with high goodness ratings from Experiment 1
Number of subjects: 0
Study 7860832 — intervention group
Group type: COMPARATOR
Intervention: Vowel tokens with low goodness ratings from Experiment 1
Number of subjects: 0
Study 2288828 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathinone
Number of subjects: 6
Study 2288828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7009002 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 28
Study 7009002 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 28
Study 31842821 — intervention group
Group type: EXPERIMENTAL
Intervention: Active DLPFC rTMS
Number of subjects: 99
Study 31842821 — intervention group
Group type: EXPERIMENTAL
Intervention: Active LPC rTMS
Number of subjects: 99
Study 31842821 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 99
Study 28483164 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite (NaOCl), n = 22
Number of subjects: 43
Study 28483164 — intervention group
Group type: COMPARATOR
Intervention: Saline, n = 21
Number of subjects: 43
Study 25911762 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electric field at Jiaji (EX-B 2) points with optimal prescription: high frequency (10^3 Hz), 0-90 V pulse amplitude, 0.4 ms pulse width, and 5 months treatment time.
Number of subjects: 56
Study 24231671 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with AC joint resection
Number of subjects: 40
Study 24231671 — intervention group
Group type: COMPARATOR
Intervention: Isolated rotator cuff repair (control group)
Number of subjects: 40
Study 21340034 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta‐tDCS during NonREM sleep
Number of subjects: 0
Study 21340034 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta‐tDCS during REM sleep
Number of subjects: 0
Study 19730217 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (EACA) 100 mg/kg
Number of subjects: 182
Study 19730217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 16965635 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone 3 mg twice daily for 5 days
Number of subjects: 25
Study 16965635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 11232497 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine monotherapy
Number of subjects: 89
Study 11232497 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine withdrawal
Number of subjects: 89
Study 8646866 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate ointment, 0.005%
Number of subjects: 74
Study 8646866 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone-17,21-dipropionate ointment, 0.05%
Number of subjects: 74
Study 1948104 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 302
Study 1948104 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 302
Study 6395232 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study 6395232 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study 31513675 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Number of subjects: 0
Study 31513675 — intervention group
Group type: COMPARATOR
Intervention: 10Hz repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 0
Study 30412068 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic agents
Number of subjects: 14139
Study 30412068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 14139
Study 27344046 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (BF) 320/9 μg delivered by Spiromax
Number of subjects: 16
Study 27344046 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol (BF) 320/9 μg delivered by Turbuhaler
Number of subjects: 16
Study 25239721 — intervention group
Group type: EXPERIMENTAL
Intervention: Decolonization with nasal mupirocin and chlorhexidine bathing, enhanced environmental cleaning with bleach every 4 months; newly admitted MRSA nares-positive residents decolonized on admission.
Number of subjects: 3
Study 25239721 — intervention group
Group type: COMPARATOR
Intervention: Control units screened but not decolonized; received periodic bleach environmental cleaning and instruction on hand hygiene.
Number of subjects: 3
Study 25239721 — intervention group
Group type: EXPERIMENTAL
Intervention: All units followed intervention protocol in year 2.
Number of subjects: 3
Study 22313076 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 10 µg/kg diluted in 10 ml saline 0.9% intravenously (group 1, n=40)
Number of subjects: 80
Study 22313076 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 ml 0.9% saline, group 2, n=40)
Number of subjects: 80
Study 20002510 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted U.S. model of pharmaceutical care
Number of subjects: 334
Study 20002510 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 334
Study 17908628 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy combined with chemotherapy
Number of subjects: 0
Study 17908628 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-modality therapy
Number of subjects: 0
Study 16257339 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/day) plus best supportive care
Number of subjects: 1692
Study 16257339 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 1692
Study 11903075 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet apheresis (c-PRP)
Number of subjects: 20
Study 11903075 — intervention group
Group type: COMPARATOR
Intervention: Control group (no apheresis)
Number of subjects: 20
Study 10103301 — intervention group
Group type: EXPERIMENTAL
Intervention: Dust control intervention (cleaning equipment and up to eight visits by a dust control advisor)
Number of subjects: 275